このエピソードについて
Transforming early detection & Precision health
Marty Keiser is an entrepreneur and the founder of IV BioHoldings, a bio platform company founded in 2018 where they conceive, create and develop 1st class liquid biopsy companies all focused on early detection and precision health.
Over the last 3 years, Marty and his team have since launched three companies out of IVBH
Liquid Lung -Pulmonary disease
Hepgene -Metabolic disease
Mammogen - Women’s health
All companies have three things in common
- Focused on very specific biological processes and systems
- All based on Novel proprietary RNA technologies
- They are not just focused on diagnostics, the comprehensive nature of their scientific platforms unlocks different insights and applications from early detection, to better and easier, more confirmatory diagnostics tools as well as guiding some therapeutic insights and more precise treatment decisions
In this week’s episode, Marty shares his story of how he got into the industry having previously worked on Wall Street.
Marty’s passion for change and eagerness to dismantle healthcare silos translates throughout the interview and is completely awe-inspiring.
